POINT Biopharma Global Inc., (PNT): Price and Financial Metrics
PNT Price/Volume Stats
| Current price | $12.50 | 52-week high | $14.35 |
| Prev. close | $12.48 | 52-week low | $6.57 |
| Day low | $12.49 | Volume | 3,290,900 |
| Day high | $12.51 | Avg. volume | 1,442,213 |
| 50-day MA | $13.22 | Dividend yield | N/A |
| 200-day MA | $9.79 | Market Cap | 1.33B |
PNT Stock Price Chart Interactive Chart >
POINT Biopharma Global Inc., (PNT) Company Bio
POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.
Latest PNT News From Around the Web
Below are the latest news stories about POINT BIOPHARMA GLOBAL INC that investors may wish to consider to help them evaluate PNT as an investment opportunity.
Lilly Completes Acquisition of POINT BiopharmaEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. |
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate CancerPhase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA) |
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. |
PNT Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -3.47% |
| 1-year | 55.47% |
| 3-year | 25.63% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 30.18% |
| 2021 | -59.77% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...